29 April 2021 | 07:47am
StockMarketWire.com - medical technology company Convatec reported an 8.7% rise in revenue in the first quarter, led by strong growth in its advanced wound care and infusion care business.
For the three months ended March 2021, revenue rose 8.7% to $500 million year-on-year.
Advanced Wound Care revenue was up 8.8% on a reported basis, while Ostomy Care, its second largest business was up 6.7%.
Infusion Care revenue increased 13.9%, and continence & critical care revenue was up 7.4%.
Looking ahead, the company maintained its full year outlook, citing ongoing macro uncertainties.
For 2021, organic revenue growth is expected to be between 3% and 4.5%.
Story provided by StockMarketWire.com
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Ostomy Care Market Dynamics, Trends, Revenue, Regional Segmented, Outlook & Forecast Till 2028 The report includes porter s Five Forces Analysis (potential entrants, industry competitors, suppliers, substitutes, and buyers), SWOT analysis and BPS analysis for every segment that provides crucial information
BriefingWire.com, 4/24/2021 - Facto Market Insights as of late distributed statistical surveying report on the worldwide Ostomy Care market (2021-2028) market to its assortment of statistical surveying reports. The exploration report covers point by point examination of market measuring and anticipating of the market covering the market drivers, challenges, opportunity investigation, and patterns, alongside different key bits of knowledge in the worldwide market. The examination report additionally incorporates the investigation of territorial producers and new market players, covering all the data reasonable for the customers to
23 August 2021.
The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the
European Parliament and Council of
16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.
The following transactions have been executed during the period 6 –
9 April 2021:
Coloplast A/S : - Transactions in connection with share buy-back programme, week 13 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.